Thus, CHIT1 and its interacting partners of TGFBRAP1 or FOXO3 could be reasonable therapeutic targets for the intervention of patients with pulmonary fibrosis in that TGF-β and CHIT1 are significantly dysregulated. Here, TGFBRAP1 is linked to pulmonary fibrosis.